Skip to main content
All lobbying filings

AMERICAN SOCIETY OF HEMATOLOGY

Lobbying for AMERICAN SOCIETY OF HEMATOLOGY

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$100,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Lobbying activity 5

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 (H.R.9260) FY2027 Continuing Appropriations Act (through 12/04/2026)(H.R. 9770) FY2027 Continuing Appropriations and Extensions Act (through 12/11/2026)(H.R. 6500) OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034)

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Issues impacting laboratory testing and pediatric reference intervals (PRIs) Clinical trials regulations and coverage Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders OMB proposed Regulation for Federal Financial Assistance (OMB-2026-0034) Clinical Trial Modernization Act (H.R. 3521 / S. 4440)

Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations for autologous stem cell transplantation for multiple myeloma Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Community engagement requirements of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936 / H.R. 9703) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)

Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261) Sickle Cell Care Expansion Act of 2026 (S. 5489) Sickle Cell Disease Treatment Centers Act of 2026 (S. 5488) Resolutions expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" (H.Res. 1577 / S.Res. 940)

H-1B visa fees and exemptions for physicians

 Bills named in this filing 18
  • H.R. 9260
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
  • H.R. 9770
    Continuing Appropriations Act, 2027
  • H.R. 6500
    Continuing Appropriations and Extensions Act, 2027
  • H.R. 3521
    Clinical Trial Modernization Act
  • S. 4440
    Clinical Trial Modernization Act
  • H.R. 879
    Medicare Patient Access and Practice Stabilization Act of 2025
  • S. 721
    Sickle Cell Disease Comprehensive Care Act
  • H.R. 5178
    Sickle Cell Disease Comprehensive Care Act
  • S. 1936
    Improving Access to Transfusion Care for Hospice Patients Act of 2025
  • H.R. 9703
    Improving Access to Transfusion Care for Hospice Patients Act of 2026
  • H.R. 3514
    Improving Seniors’ Timely Access to Care Act of 2025
  • S. 1816
    Improving Seniors’ Timely Access to Care Act of 2025
  • H.R. 4206
    CONNECT for Health Act of 2025
  • S. 1261
    CONNECT for Health Act of 2025
  • S. 5489
    Sickle Cell Care Expansion Act of 2026
  • S. 5488
    Sickle Cell Disease Treatment Centers Act of 2026
  • H. Res. 1577
    Expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" in order to educate c…
  • S. Res. 940
    A resolution expressing support for the designation of September 2026 as "Sickle Cell Disease Awareness Month" in order…

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem